id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-D-5928-0009,FDA,FDA-2017-D-5928,Post-Complete Response Letter Clarification Teleconferences Between FDA and ANDA Applicants Under GDUFA; Guidance for Industry - Revision 1,Other,Guidance,2022-10-05T04:00:00Z,2022,10,2022-10-05T04:00:00Z,,2024-11-07T01:32:51Z,,1,0,09000064853bac1b
FDA-2017-D-5928-0008,FDA,FDA-2017-D-5928,Post-Complete Response Letter Meetings Between FDA and ANDA Applicants Under GDUFA Guidance for Industry,Other,Guidance,2018-12-04T05:00:00Z,2018,12,2018-12-04T05:00:00Z,,2022-10-05T19:14:56Z,,0,0,090000648390cf2c
FDA-2017-D-5928-0007,FDA,FDA-2017-D-5928,"Post-Complete Response Letter Meetings Between the Food and Drug
Administration and Abbreviated New Drug Application Applicants Under
Generic Drug User Fee Amendments; Guidance for Industry; Availability",Notice,Notice of Availability,2018-12-04T05:00:00Z,2018,12,2018-12-04T05:00:00Z,,2022-10-05T19:15:10Z,2018-26285,0,0,0900006483939624
FDA-2017-D-5928-0001,FDA,FDA-2017-D-5928,"Post-Complete Response Letter Meetings Between the Food and Drug 
Administration and Abbreviated New Drug Application Applicants Under 
the Generic Drug User Fee Act; Draft Guidance for Industry; Availability",Notice,Notice of Availability,2017-10-16T04:00:00Z,2017,10,2017-10-16T04:00:00Z,2017-12-16T04:59:59Z,2017-12-16T02:02:44Z,2017-22288,0,0,0900006482bcd99e
FDA-2017-D-5928-0002,FDA,FDA-2017-D-5928,Guidance for Industry on Response Letter Meetings Between FDA and ANDA Applicants Under GDUFA,Other,Guidance,2017-10-16T04:00:00Z,2017,10,2017-10-16T04:00:00Z,,2024-11-07T01:18:52Z,,1,0,0900006482bcddde